Free Trial

Grail Q4 2024 Earnings Report

Grail logo
$31.20 -0.93 (-2.89%)
As of 03/25/2025 04:00 PM Eastern

Grail EPS Results

Actual EPS
-$1.86
Consensus EPS
-$4.41
Beat/Miss
Beat by +$2.55
One Year Ago EPS
N/A

Grail Revenue Results

Actual Revenue
$38.25 million
Expected Revenue
$35.33 million
Beat/Miss
Beat by +$2.92 million
YoY Revenue Growth
N/A

Grail Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Grail Earnings Headlines

Grail price target raised to $20 from $16 at Morgan Stanley
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Why Grail (GRAL) Is Falling Today
See More Grail Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grail? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grail and other key companies, straight to your email.

About Grail

Grail (NASDAQ:GRAL) is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

View Grail Profile

More Earnings Resources from MarketBeat